DelveInsight’s Yellow Fever Pipeline Insight 2022 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Yellow Fever pipeline landscape.
Yellow Fever Pipeline landscape is provided which includes the disease overview and Yellow Fever treatment guidelines. The assessment part of the Yellow Fever pipeline report embraces, in depth Yellow Fever commercial assessment and clinical assessment of the pipeline products under development. In the Yellow Fever Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Yellow Fever Pipeline Report
- DelveInsight’s Yellow Fever Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for various indications.
- Leading Yellow Fever Companies such as BioCryst Pharmaceuticals, Tychan Pte Ltd., CureVac AG, Serum Institute of India Ltd, Sanofi, Emergex Vaccines, Imutex Ltd, and many others are evaluating new Yellow Fever Pipeline to improve the treatment therapies.
- Promising Yellow Fever therapies in the pipeline in various stages of development include XRX-001, TY014, YF-17D, TDV, and many others.
- Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. BioCryst is developing Galidesivir in collaboration with U.S. government agencies and other institutions. Galidesivir is an adenosine nucleoside analog that acts to block viral RNA polymerase. BioCryst Pharmaceuticals completed phase I for Galidesivir.
- TY014 is the first monoclonal antibody designed and engineered to treat yellow fever virus infections. TY014 is directed against the envelope (E) protein on the surface of the virus, and prevents viral replication by limiting viral fusion to host cells. Phase 1A of the TY014 study evaluated safety, tolerability and pharmacokinetics of this monoclonal antibody in healthy volunteers
Request a sample and discover the recent advances in Yellow Fever @ Yellow Fever Pipeline Outlook
The Yellow Fever Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Yellow Fever, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Yellow Fever Pipeline Landscape.
Yellow Fever Overview
Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow fever virus is an arbovirus of the flavivirus genus and is transmitted by mosquitoes, belonging to the Aedes and Haemagogus species. Yellow fever appears with a sudden onset of fever, chills, headache, backache, nausea, and vomiting. The majority of people infected with yellow fever virus will either not have symptoms, or have mild symptoms and completely recover. Yellow fever is difficult to diagnose, especially during the early stages. More commonly it is diagnosed based on laboratory testing, a person’s symptoms, and travel history. Good and early supportive treatment in hospitals improves survival rates. There is no medicine to treat or cure infection from yellow fever. Vaccination is the most important means of preventing yellow fever.
- Yellow fever offers a severe worldwide threat that necessitates new strategic thinking, as evidenced by two connected urban epidemics in 2016 in Luanda (Angola) and Kinshasa (Democratic Republic of the Congo), with greater international exportation from Angola to other nations, including China.
- In response to the growing danger of urban yellow fever outbreaks that spread internationally, the Eliminate Yellow Fever Epidemics (EYE) Strategy was created. EYE supports 40 countries and works with more than 50 partners under the direction of WHO, UNICEF, and Gavi, the Vaccine Alliance.
Key facts of the Yellow Fever Pipeline Report
- Acute viral hemorrhagic disease called yellow fever is spread by infected mosquitoes. The name’s “yellow” component alludes to the jaundice that some patients experience.
- Only a small percentage of persons who catch the virus experience severe symptoms, and around half of them pass away within 7 to 10 days.
- Tropical regions of Africa, Central and South America are affected by the virus.
Yellow Fever Pipeline Analysis Report
- The Yellow Fever Pipeline report provides detailed insights about emerging therapies for the treatment of Anthrax and the aggregate therapies developed by major pharma companies.
- It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Yellow Fever Treatment.
- It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- The Yellow Fever Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Yellow Fever market.
The Yellow Fever Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of the Yellow Fever Pipeline Report
- Coverage- Global
- Yellow Fever Pipeline Assessment by Phases- Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I) along with the details of, Pre-clinical and Discovery stage candidate, Discontinued & Inactive Candidates
- Yellow Fever Pipeline Assessment by Route of Administration- Oral, Parenteral, Intravitreal, Subretinal, Topical, Molecule Type
- Yellow Fever Pipeline Assessment by Molecule Type- Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy, Product Type
- Yellow Fever Companies- BioCryst Pharmaceuticals, Tychan Pte Ltd., CureVac AG, Serum Institute of India Ltd, Sanofi, Emergex Vaccines, Imutex Ltd, and many others
- Yellow Fever Therapies- XRX-001, TY014, YF-17D, TDV, and many others
Dive deep into rich insights for Yellow Fever Pipeline Assessment, Visit @ Yellow Fever Pipeline Therapeutics Assessment
Table of Content
- Executive Summary
- Yellow Fever: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Yellow Fever – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Yellow Fever Collaboration Deals
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Early Stage Products (Phase I)
- Galidesivir: BioCryst Pharmaceuticals
- Preclinical Products
- EMX-001: Emergex Vaccines
- Inactive Products
- Yellow Fever Key Companies
- Yellow Fever Key Products
- Yellow Fever- Unmet Needs
- Yellow Fever- Market Drivers and Barriers
- Yellow Fever- Future Perspectives and Conclusion
- Yellow Fever Analyst Views
- Yellow Fever Key Companies
For further information on the Yellow Fever Pipeline therapeutics, reach out @ Yellow Fever Pipeline Landscape
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States